
Medical illustration: Analgesic Drug Delivery for Osteoarthritis
Created for Eupraxia Pharmaceuticals Inc.
Link copied!


The project
Eupraxia’s proprietary drug-delivery technology provides a consistent dose over 6 months. To demonstrate how it maintains stable drug concentrations within target tissue, we developed two figures, illustrating applications being studied in clinical trials: osteoarthritis (OA) and eosinophilic esophagitis (EoE). These called for an anatomically accurate knee joint, highlighting key OA-related pathology and a section view of esophagus with (EoE) pathology and proposed drug injection sites. We designed the layout to easily accommodate future clinical applications for EP-104 drug delivery technology.
Created for
Eupraxia Pharmaceuticals Inc.